Healthy Volunteer Study of Clopidogrel and Rifampicin
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The principal research question is: Can platelet P2Y12 receptor blockade by the
antithrombotic drug clopidogrel be significantly enhanced by coadministration of the
antibiotic rifampicin?
Clopidogrel is an antithrombotic drug in clinical use that reduces the risk of heart attack
and coronary stent thrombosis. However some patients respond poorly to clopidogrel, at least
partly because they fail to convert it effectively to its active form, and consequently are
at higher risk of arterial thrombosis. Preliminary evidence indicates that the antibiotic
rifampicin enhances the effectiveness of clopidogrel by increasing its conversion to its
active form by the liver. We wish to study further the extent of rifampicin's effect on
clopidogrel to see whether this might be useful in clinical practice.